Tam Dao

Ms. Tam Dao


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2020 in Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
TDTam Dao
Tam Dao
AGAlexander Green
Alexander Green
YKYun A Kim
Yun A Kim
SBSung-Jin Bae
Sung-Jin Bae
KHKi-Tae Ha
Ki-Tae Ha
Dongryeol RyuDongryeol Ryu
Dongryeol Ryu
The world is facing the new challenges of an aging population, and understanding the process of aging has therefore become one of the most important global concerns. Sarcopenia is a condition which is defined by the gradual loss of skeletal muscle mass and function with age. In research and clinical practice, sarcopenia is recognized as a component of geriatric disease and is a current target for drug development. In this review we define this condition and provide an overview of current therapeutic approaches. We further highlight recent findings that describe key pathophysiological phenotypes of this condition, including alterations in muscle fiber types, mitochondrial function, nicotinamide adenine dinucleotide (NAD+) metabolism, myokines, and gut microbiota, in aged muscle compared to young muscle or healthy aged muscle. The last part of this review examines new therapeutic avenues for promising treatment targets. There is still no accepted therapy for sarcopenia in humans. Here we provide a brief review of the current state of research derived from various mouse models or human samples that provide novel routes for the development of effective therapeutics to maintain muscle health during aging.

28 February 2026 in Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
TNThanh T. Nguyen
Thanh T. Nguyen
TDTam Dao
Tam Dao
HNHa Thu Nguyen
Ha Thu Nguyen
JPJun-Hyeon Park
Jun-Hyeon Park
JSJeong Seung-Jun
Jeong Seung-Jun
Dongryeol RyuDongryeol Ryu
Dongryeol Ryu
Sarcopenia is a progressive, age-related condition characterized by the loss of skeletal muscle mass, strength, and function, which increases the risk of falls, frailty, and loss of independence. Despite growing recognition and its incorporation into geriatric assessments, there is still no approved pharmacological treatment. This review provides an updated overview of sarcopenia, encompassing diagnostic criteria, biological mechanisms, and emerging therapeutic strategies. Key molecular features include mitochondrial dysfunction, nicotinamide adenine dinucleotide (NAD⁺) decline, fiber-type alterations, and dysregulation of myokines. Recent singlecell and multi-omics studies have revealed the heterogeneity of muscle tissue and distinct cell-type-specific aging patterns. Therapeutic efforts are evolving beyond lifestyle interventions toward targeted approaches, including myostatin inhibitors, NAD⁺ boosters, senolytics, and microbiome modulators. However, clinical translation remains constrained by heterogeneity in trial design and the absence of standardized outcome measures. Future sarcopenia care will likely involve precision medicine guided by biomarkers and supported by digital monitoring tools. Progressing from molecular discovery to clinical application will be essential for preserving muscle health and function in aging populations.

1 January 2025 in Biomaterials Research
Verified
Journal Article
Closed access
SWShibo Wei
Shibo Wei
PTPhuong Le Thi
Phuong Le Thi
YZYan Zhang
Yan Zhang
MPMoon-Young Park
Moon-Young Park
KDKhanh Do
Khanh Do
Dongryeol RyuDongryeol Ryu
Dongryeol Ryu
Cellular senescence, a process that induces irreversible cell cycle arrest in response to diverse stressors, is a primary contributor to aging and age-related diseases. Currently, exposure to hydrogen peroxide is a widely used technique for establishing in vitro cellular senescence models; however, this traditional method is inconsistent, laborious, and ineffective in vivo. To overcome these limitations, we have developed a hydrogen peroxide-releasing hydrogel that can readily and controllably induce senescence in conventional 2-dimensional cell cultures as well as advanced 3-dimensional microphysiological systems. Notably, we have established 2 platforms using our hydrogen peroxide-releasing hydrogel for investigating senolytics, which is a promising innovation in anti-geronic therapy. Conclusively, our advanced model presents a highly promising tool that offers a simple, versatile, convenient, effective, and highly adaptable technique for inducing cellular senescence. This innovation not only lays a crucial foundation for future research on aging but also markedly accelerates the development of novel therapeutic strategies targeting age-related diseases.

17 October 2024 in Research Square
Verified
Preprint
Open access
PDF file
Jang Hyun ChoiJang Hyun Choi
Jang Hyun Choi
YLYo Han Lee
Yo Han Lee
JLJinyoung Lee
Jinyoung Lee
JJJoonho Jeong
Joonho Jeong
KPKieun Park
Kieun Park
HYHwayoung Yun
Hwayoung Yun
Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a global health challenge with limited therapeutic options, and its molecular mechanisms remain poorly understood. Here, we identify microRNA-93 (miR-93) as a critical regulator of MASLD progression. miR-93 was markedly upregulated in liver tissues from both MASLD patients and diet-induced obese mice. miR-93 knockout (KO) mice were protected against diet-induced hepatic steatosis and fibrosis, along with improved glucose tolerance and enhanced mitochondrial function. Transcriptomic analysis revealed that miR-93 directly targets Sirtuin 1 (SIRT1), suppressing the LKB1-AMPK signaling pathway, which disrupts lipid metabolism. Notably, pharmacological inhibition of miR-93 using niacin restored SIRT1 activity, alleviating MASLD symptoms and improving metabolic function. Our findings establish miR-93 as a novel and promising therapeutic target in MASLD. The modulation of the miR-93/SIRT1 axis, particularly through niacin treatment, presents a potential therapeutic avenue for MASLD, a disease with few current treatment options.

26 October 2026 in Advanced Functional Materials
Verified
Journal Article
Closed access
SKSung Dong Kim
Sung Dong Kim
SWShibo Wei
Shibo Wei
YZYan Zhang
Yan Zhang
WPWonyoung Park
Wonyoung Park
TDTam Dao
Tam Dao
Mikyung ShinMikyung Shin
Mikyung Shin